NCT05317819 2025-12-18
Study of ADI-PEG 20 Versus Placebo in Subjects With High Arginine Level and Unresectable Hepatocellular Carcinoma
Polaris Group
Phase 3 Recruiting
Clinical Trials
10 trialsNCT06034977 2023-09-13
Phase 2 Study of ADI-PEG 20 Plus Lenvatinib Treatment in Subjects With Unresectable Hepatocellular Carcinoma
Chang Gung Memorial Hospital
Phase 2 Recruiting
NCT04965714 2023-02-16
Nivolumab and ADI-PEG 20 Before Surgery for the Treatment of Resectable Liver Cancer
M.D. Anderson Cancer Center
Phase 2 Withdrawn
NCT02102022 2022-04-25
Ph 1-2 Study ADI-PEG 20 Plus FOLFOX in Subjects With Advanced GI Malignancies Focusing on Hepatocellular Carcinoma
Polaris Group
Phase 1/2 Terminated
NCT02101580 2020-10-01
Ph 1B Trial With ADI-PEG 20 Plus Nab-Paclitaxel and Gemcitabine in Subjects With Pancreatic Cancer
Polaris Group
Phase 1 Completed
NCT02029690 2020-09-25
TRAP
Polaris Group
Phase 1 Terminated
NCT01287585 2019-09-06
ADI-PEG 20
Polaris Group
Phase 3 Completed
NCT02006030 2018-09-04
TACE
Polaris Group
Phase 2 Completed
NCT02101593 2016-03-04
Ph 1 Trial of ADI PEG 20 Plus Sorafenib to Treat Patients With Liver Cancer
Polaris Group
Phase 1 Completed
NCT00056992 2015-03-25
Testing of ADI-PEG in Hepatocellular Carcinoma
FDA Office of Orphan Products Development
Phase 2 Completed